According to MBS’ press release, the BBI Group, partner to the world’s leading diagnostic and healthcare organisations, has entered into a definitive agreement to acquire the Maine Biotechnology Services, Inc. (MBS) located in Portland, Maine (USA). The acquisition of MBS will expand BBI’s portfolio during a period of expansion and growth. The company provides a range of products to the diagnostic, healthcare, research food sectors globally. MBS will add antibody development to its capability and product range. Read full story
Related Posts
Maine’s first mobile biolab starts tour of rural schools in Fort Kent
FORT KENT, Maine — Fort Kent middle schoolers are the state’s first students to learn at the newly unveiled Maine Mobile Biolab, a 50-foot,...
UMaine Augusta’s $1.75M medical lab training facility doubles student capacity
Anew medical lab training facility on the campus of University of Maine Augusta is nearly six times larger than an off-campus space...
UNE receives grant to research state-threatened animal
The University of New England has received a grant from the Maine Department of Inland Fisheries and Wildlife to study one...